{
  "id": 6731751,
  "title": "Kazia Therapeutics doses first patient in paediatric brain cancer trial",
  "url": "https://urgent.news/2026/09/11/kazia-therapeutics-doses-first-patient-in-paediatric-brain-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-11T07:54:36.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/kazia-therapeutics-doses-first-patient-in-paediatric-brain-cancer-trial-160491.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Kazia Therapeutics initiated dosing in its PNOC035 clinical study evaluating drug candidate paxalisib alongside gemcitabine for children and young adults with recurrent AT RT brain cancer",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}